In prostate cancer, in which survival is highly dependent on steroidogenesis, CYP17A1 promotes prostate cancer progression and reduces the chemotherapeutic efficiency.6, 14, 15 In brain tissue, CYP17A1-mediated DHEA production may promote GBM to become more malignant and resistant to TMZ. Here, CYP17A1 is linked to prostate carcinoma.